Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by Bank of New York Mellon Corp

Key Points

• The Bank of New York Mellon Corp increased its holdings in Takeda Pharmaceutical by 23.4% in the first quarter, now owning 129,479 shares valued at approximately $1.93 million.
• Takeda's latest earnings report showed an EPS of $0.16, missing analysts' expectations of $0.24, with revenue also falling short at $7.34 billion compared to forecasts of $8.02 billion.
• Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" to "overweight" rating in early April, indicating increased confidence in the stock's performance.

Bank of New York Mellon Corp grew its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 23.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 129,479 shares of the company's stock after purchasing an additional 24,587 shares during the quarter. Bank of New York Mellon Corp's holdings in Takeda Pharmaceutical were worth $1,925,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Jackson Thornton Wealth Management LLC acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $174,000. Catalyst Capital Advisors LLC grew its position in shares of Takeda Pharmaceutical by 1.7% during the first quarter. Catalyst Capital Advisors LLC now owns 181,000 shares of the company's stock worth $2,691,000 after acquiring an additional 3,000 shares during the last quarter. Checchi Capital Advisers LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $177,000. Vontobel Holding Ltd. purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $262,000. Finally, Intelligence Driven Advisers LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth approximately $202,000. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded up $0.45 during mid-day trading on Friday, reaching $14.17. 6,215,654 shares of the company's stock were exchanged, compared to its average volume of 2,432,449. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.01 and a quick ratio of 0.52. The stock has a market capitalization of $45.09 billion, a PE ratio of 47.23 and a beta of 0.23. The business's fifty day simple moving average is $14.87 and its 200-day simple moving average is $14.50. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to analysts' expectations of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.52% and a net margin of 3.20%. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.